4.8 Article

miRISC recruits decapping factors to miRNA targets to enhance their degradation

期刊

NUCLEIC ACIDS RESEARCH
卷 41, 期 18, 页码 8692-8705

出版社

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkt619

关键词

-

资金

  1. Max Planck Society
  2. Deutsche Forschungsgemeinschaft [DFG] [FOR855]
  3. Toyobo Biotechnology Foundation

向作者/读者索取更多资源

MicroRNA (miRNA)-induced silencing complexes (miRISCs) repress translation and promote degradation of miRNA targets. Target degradation occurs through the 5'-to-3' messenger RNA (mRNA) decay pathway, wherein, after shortening of the mRNA poly(A) tail, the removal of the 5' cap structure by decapping triggers irreversible decay of the mRNA body. Here, we demonstrate that miRISC enhances the association of the decapping activators DCP1, Me31B and HPat with deadenylated miRNA targets that accumulate when decapping is blocked. DCP1 and Me31B recruitment by miRISC occurs before the completion of deadenylation. Remarkably, miRISC recruits DCP1, Me31B and HPat to engineered miRNA targets transcribed by RNA polymerase III, which lack a cap structure, a protein-coding region and a poly(A) tail. Furthermore, miRISC can trigger decapping and the subsequent degradation of mRNA targets independently of ongoing deadenylation. Thus, miRISC increases the local concentration of the decapping machinery on miRNA targets to facilitate decapping and irreversibly shut down their translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation

Maninjay K. Atianand, Wenqian Hu, Ansuman T. Satpathy, Ying Shen, Emiliano P. Ricci, Juan R. Alvarez-Dominguez, Ankit Bhatta, Stefan A. Schattgen, Jason D. McGowan, Juliana Blin, Joerg E. Braun, Pallavi Gandhi, Melissa J. Moore, Howard Y. Chang, Harvey F. Lodish, Daniel R. Caffrey, Katherine A. Fitzgerald

Article Biology

Synergistic assembly of human pre-spliceosomes across introns and exons

Joerg E. Braun, Larry J. Friedman, Jeff Gelles, Melissa J. Moore

Article Biochemistry & Molecular Biology

A DDX6-CNOT1 Complex and W-Binding Pockets in CNOT9 Reveal Direct Links between miRNA Target Recognition and Silencing

Ying Chen, Andreas Boland, Duygu Kuzuoglu-Ozturk, Praveen Bawankar, Belinda Loh, Chung-Te Chang, Oliver Weichenrieder, Elisa Izaurralde

MOLECULAR CELL (2014)

Article Biochemistry & Molecular Biology

An asymmetric PAN3 dimer recruits a single PAN2 exonuclease to mediate mRNA deadenylation and decay

Stefanie Jonas, Mary Christie, Daniel Peter, Dipankar Bhandari, Belinda Loh, Eric Huntzinger, Oliver Weichenrieder, Elisa Izaurralde

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)

Article Biochemistry & Molecular Biology

The activation of the decapping enzyme DCP2 by DCP1 occurs on the EDC4 scaffold and involves a conserved loop in DCP1

Chung-Te Chang, Natalia Bercovich, Belinda Loh, Stefanie Jonas, Elisa Izaurralde

NUCLEIC ACIDS RESEARCH (2014)

Article Oncology

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer

Bastian J. Schmied, Fabian Riegg, Latifa Zekri, Ludger Grosse-Hovest, Hans-Joerg Buehring, Gundram Jung, Helmut R. Salih

CANCERS (2019)

Article Oncology

Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody

Bastian J. Schmied, Martina S. Lutz, Fabian Riegg, Latifa Zekri, Jonas S. Heitmann, Hans-Joerg Buehring, Gundram Jung, Helmut R. Salih

CANCERS (2019)

Article Oncology

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Joseph Kauer, Sebastian Hoerner, Lukas Osburg, Stefanie Mueller, Melanie Maerklin, Jonas S. Heitmann, Latifa Zekri, Hans-Georg Rammensee, Helmut R. Salih, Gundram Jung

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Medicine, Research & Experimental

An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer

Latifa Zekri, Fabian Vogt, Lukas Osburg, Stefanie Mueller, Joseph Kauer, Timo Manz, Martin Pfluegler, Andreas Maurer, Jonas S. Heitmann, Ilona Hagelstein, Melanie Maerklin, Sebastian Hoerner, Tilmann Todenhoefer, Carsten Calaminus, Arnulf Stenzl, Bernd Pichler, Christian laFougere, Marc A. Schneider, Hans-Georg Rammensee, Lars Zender, Bence Sipos, Helmut R. Salih, Gundram Jung

Summary: The PSMA antibody 10B3 exhibits superior dual reactivity on prostate carcinoma and squamous cell carcinoma tissues, and is used to construct T-cell recruiting bispecific antibodies IgGsc, which show better efficacy in eliminating tumors. Treatment with IgGsc in three patients with metastasized prostate carcinoma resulted in significant T-cell activation and rapid reduction of elevated PSA levels.

EMBO MOLECULAR MEDICINE (2021)

Article Oncology

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies

Joseph Kauer, Fabian Vogt, Ilona Hagelstein, Sebastian Hoerner, Melanie Maerklin, Stefanie Maurer, Helmut R. Salih, Gundram Jung, Latifa Zekri

Summary: Bispecific antibodies are effective in activating T cells against cancer, but can also cause cytokine release syndrome. Blocking the adhesion molecule CD18 can reduce unwanted T cell activation without affecting the anti-tumor effect. This opens up the possibility of preventing off-target T cell activation and allowing for effective doses of bispecific antibodies.

CANCERS (2021)

Article Oncology

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies

Martina Svenja Lutz, Boris Klimovich, Stefanie Maurer, Jonas S. Heitmann, Melanie Maerklin, Latifa Zekri, Gundram Jung, Helmut R. Salih, Clemens Hinterleitner

Summary: This study found that platelet activation reduces the efficacy of T cell-recruiting antibodies, and the effect can be restored by blocking the transforming growth factor beta (TGF-beta) axis.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Naveen K. Mehta, Martin Pfluegler, Kristan Meetze, Bochong Li, Isabelle Sindel, Fabian Vogt, Melanie Marklin, Jonas S. Heitmann, Joseph Kauer, Lukas Osburg, Latifa Zekri, Hans-Joerg Buehring, Stefanie Mueller, Sebastian Hoerner, Patrick A. Baeuerle, Jennifer S. Michaelson, Gundram Jung, Helmut R. Salih

Summary: Immunotherapeutic strategies using CAR-T cells and bsAbs have achieved remarkable clinical success in lymphoid malignancies but not in acute myeloid leukemia (AML). This study developed a bsAb, CLN-049, targeting FLT3 and demonstrated its favorable efficacy and safety profile in preclinical models, indicating its potential as a treatment option for AML.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Immunology

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma

Ilona Hagelstein, Monika Engel, Clemens Hinterleitner, Timo Manz, Melanie Maerklin, Gundram Jung, Helmut R. Salih, Latifa Zekri

Summary: This study found that B7-H3 is highly expressed in bone and soft-tissue sarcomas, and proposed the use of a B7-H3 monoclonal antibody with a variant Fc part to enhance NK cell cytotoxicity. The results demonstrate the potential of this antibody to effectively kill various types of sarcoma cells.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases

Sebastian Horner, Moustafa Moustafa-Oglou, Karin Teppert, Ilona Hagelstein, Joseph Kauer, Martin Pfluegler, Kristina Neumann, Hans-Georg Rammensee, Thomas Metz, Andreas Herrmann, Helmut R. Salih, Gundram Jung, Latifa Zekri

Summary: This article presents a novel approach to selectively induce apoptosis in lymphoma cells and autoreactive B cells using bispecific antibodies. The developed IgG-based bispecific antibodies show efficient depletion of malignant and autoreactive B cells in vitro and in vivo.

CANCERS (2022)

Article Biotechnology & Applied Microbiology

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers

Latifa Zekri, Martina Lutz, Nisha Prakash, Timo Manz, Boris Klimovich, Stefanie Mueller, Sebastian Hoerner, Ilona Hagelstein, Monika Engel, Anna Chashchina, Martin P. fl Uegler, Jonas S. Heitmann, Gundram Jung, Helmut R. Salih

Summary: T cell-based immunotherapy has been revolutionary in oncological treatment, but its effectiveness in gastrointestinal cancers is limited. The overexpression of B7-H3 in colorectal cancer (CRC) provides a potential target for therapeutic treatment. A panel of bispecific antibodies targeting B7-H3 and CD3 was generated, and a lead compound (CC-3) showed promising results in vitro and in vivo, demonstrating strong antitumor activity. CC-3 is currently undergoing production to enable evaluation in a clinical study for CRC treatment.

MOLECULAR THERAPY (2023)

暂无数据